$4.00
0.010.25%
Últ. Act.: Oct 28, 7:56 PM
Vanda Pharmaceuticals (VNDA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vanda Pharmaceuticals (VNDA) publicó su última previsión de octubre 28, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de para el período.
En comparación con la previsión anterior, Vanda Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $240M - $290M.
Vanda Pharmaceuticals ha emitido 10 actualizaciones de orientación entre el noviembre 2, 2022 y el agosto 5, 2026. During this period, the company raised its outlook 4 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.69 | $-0.57 | $-0.66 | $-1.67 |
| Actual | $-0.37 | $-1.04 | $-0.82 | $-2.39 |
| Surprise | +46.4% | -82.5% | -24.2% | -43.1% |
| Revenue | ||||
| Estimate | $68.5M | $62.1M | $54.7M | $59.1M |
| Actual | $69.8M | $50.5M | $51.7M | $57.2M |
| Surprise | +1.96% | -18.6% | -5.52% | -3.20% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.48 | $-0.38 | $-0.23 | $-0.15 |
| Revenue | ||||
| Consensus | $77.2M | — | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $-0.37 | $-0.69 | 46.4 % |
| Q2 | Aug 5, 2026 | $-1.04 | $-0.57 | -82.5 % |
| Q1 | May 6, 2026 | $-0.82 | $-0.66 | -24.2 % |
| Q4 | Feb 11, 2026 | $-2.39 | $-1.67 | -43.1 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 28, 2026 | $69.82M | $68.47M | 1.96 % |
| Q2 | Aug 5, 2026 | $50.53M | $62.07M | -18.6 % |
| Q1 | May 6, 2026 | $51.72M | $54.74M | -5.52 % |
| Q4 | Feb 11, 2026 | $57.22M | $59.11M | -3.20 % |